


What's Inside

Opinion	2
Donor profile: Elizabeth Fyffe	2
Researcher profile: Tim Karl, Ritchie Foundation Fellow	3
Ask Garvan	3
Feature: Personalised Cancer Care	4
Staff profile: Ebi Cocodia	6
Volunteer profile: Joan & Rob Neilson	6
A Precious Gift	6
Garvan Open Day	7
Volunteers Needed for Clinical Trials	8
In memoriam	8



Garvan researchers have found that aggressive breast cancers, unresponsive to the drug Tamoxifen (one of the most effective breast cancer treatments available), can be permanently put to sleep. The discovery by Dr Alex Swarbrick, head of Garvan's Tumour Progression Research Group, received worldwide media attention when it was released in a prestigious international journal earlier this year. For an update on the latest Garvan research into breast cancer and prostate cancer see our feature story on page 4.

Dianne Lavender, Editor

Making News

■ Garvan scientists in the Bone Research Program have shown that there is a link between prostate cancer and a higher risk of bone fracture. Men with prostate cancer face a 50% higher risk of fracture, which increases to nearly double the risk if they are receiving treatment.

The Bone Research Program has also collaborated with the Icelandic genetics company, de Code, to undertake the first ever extensive genome-wide search to find genes linked to osteoporosis and bone fracture. Five regions of interest have been identified that appear to warrant further scientific investigation. There are 30,000 genes in the human genome, but until now few have been

unequivocally linked to osteoporosis. Data for both these finds came from Garvan's Dubbo Osteoporosis Epidemiology Study.

■ Garvan scientists in the Diabetes and Obesity Program have found that people who produce low levels of the molecule PYY have a higher risk of developing Type 2 diabetes and obesity. It may soon be possible to determine levels of hormone PYY through a simple blood test to determine if someone is predisposed to Type 2 diabetes. It may then be possible to use preventative treatment, slow down or even halt the illness.

■ A study by Prof Ken Ho's Pituitary Research Unit concluded that a placebo effect may contribute to how athletes

think they perform and how they actually perform when they believe they are on active treatment, particularly men. The study highlights the power of the mind in sport and indicates that the placebo effect of an athlete simply believing they are on active performing-enhancing treatment may be enough to improve perceived and actual physical performance.

■ Garvan researcher Rebecca Hinshelwood received the highly coveted \$10,000 Premier's Award for Outstanding Cancer Research Scholar from the Cancer Institute of NSW. Rebecca, a PhD student, was recognised for her research on epigenetic changes in breast cancer.



Opinion



The success of any major medical research institute is critically dependent on community support – not only for direct critical funding of new initiatives, specialised equipment and younger researchers, but also indirectly for government funding of infrastructure.

While Garvan is very proud of its strong community support and places particular emphasis on the series of public forums held each year, we have also decided to hold our first Open Day on Sunday August 17 from 10am to 1pm. The day will be aimed at providing an opportunity for supporters and their families, local residents and anyone interested in medical research to see first hand how a research institute operates.

As well as a series of “expo” – style booths demonstrating our work in different disease areas, there will be updates on diabetes and cancer research and a panel discussion on “the future of science and medicine”.

Clearly the future is a very exciting one for medical research and with a growing emphasis on “personalised” medicine and better understanding of the role of genes and environment in disorders as diverse as cancer and Alzheimer’s, we hope that the panel discussion will generate plenty of audience participation.

Everyone is warmly invited.

Professor John Shine AO FAA
Executive Director

Donor Profile: Elizabeth Fyffe

Elizabeth Fyffe is one of the most spirited, fast-moving 82-year olds you would ever hope to meet, and has been a staunch supporter of the St Vincent’s Campus for almost all her life. Her involvement started at 18, when she came to Sydney from Tamworth to do four years of live-in nursing training under the Sisters of Charity: “I always knew I wanted to be a nurse, from a very early age. Every day before we could start, Sister Asumpta had to check our nails and hair and only then were we allowed into the wards. We got one night off each week when we could go dancing with the residents at the Trocadero, but like Cinderella we had to be back by midnight (or if we were very lucky, we got a 1am pass)”.

Elizabeth thinks very highly of the discipline and standards of nursing drilled by the Sisters, and laments some of the changes evident since 1985 when nurse training was handed over to the tertiary education sector: “Not one of our contingent suffered a bad back because we were all taught to pitch in and help each other when lifting or turning. We were not allowed to have the lights on at night so as not to disrupt patients’ sleep. We were taught to change dressings, catheterize, toilet, even manage cardiac arrest by torchlight. If we didn’t know the answer to a relative’s question, we’d make the effort to go and find out.”



Elizabeth married Alec in the late 1940s, moved to Kensington and worked at St Vincent’s till the late 1960s when the lack of parking became a problem (largely because of the creation of the Garvan in 1963). She nursed until retirement in the 1970s, and sadly lost Alec in 2005.

Elizabeth was diagnosed with osteoporosis 25 years ago, when she was trying to take her rings off and a finger joint fractured spontaneously. That’s why she chooses to support osteoporosis research at the Garvan, both in terms of significant donations and a bequest she has made in her will. She remains actively involved on the Graduate Nurses Committee of St Vincent’s.

Did you know?

For every dollar Garvan spends on research, the community benefits by at least \$5 (*Access Economics*).

Quiz

1. There are 15,000 microscopic cells located in the cochlea which are essential for hearing. What are these cells called?
2. More than 50% of breast cancer cases currently have no apparent explanation. True or False?
3. Which high profile Australian singer will soon be appearing in a Garvan diabetes community service announcement for TV?

Answers:
1. Hair cells
2. True
3. Marcia Hines

Researcher Profile: Tim Karl, Ritchie Foundation Fellow

What is the current focus of your research?

I'm a Senior Research Officer in the neuroscience research department and my work explores the interactive effects of genetic and environmental changes in mental disorders. Currently, we are investigating how schizophrenia-related behaviours are affected by two main constituents of the cannabis plant. Eventually we want to establish new, highly specific mouse models of schizophrenia to better understand the mechanisms of this mental disorder.

At the moment we are also setting up a Behavioural Phenotyping Unit at the Prince of Wales Medical Research Institute (POWMRI). Based on the outcomes of our work conducted here at the Garvan, I now have the opportunity to establish an independent research group at POWMRI within the next few months.

What are some of the recent findings from your work?

We have found strong evidence suggesting that a genetic predisposition for schizophrenia may increase susceptibility to the neuro-behavioural effects of cannabis resulting in more

rapid development of tolerance to this drug. Interestingly, acute but not chronic exposure to cannabis seems to reverse some of the symptoms of schizophrenia. This research might help explain the high number of cannabis abusers among schizophrenia patients.

What is the biggest challenge in your area of research?

Obviously, getting funding for our work is always a challenge. So we are extremely grateful for the continuous support of the Schizophrenia Research Institute. I am also indebted to the Ritchie family for the privilege of their Fellowship support over the past two years. Science-related issues of standardisation and the appropriate use of mice models for complex human disorders such as schizophrenia are also a challenge for us.

What do you enjoy doing away from the research lab?

I am originally from Germany and one of the reasons I moved to Australia was to enjoy life outside work. I enjoy scuba diving, all sorts of sport, travelling within and outside the country as well as lots of super 14 / test match action.



Ask Garvan...

How is Garvan's annual public seminar program put together?

The annual seminar program is part of Garvan's commitment to sharing its knowledge with the Australian community, a commitment which is actually a formal part of our charter.

In the last quarter of each calendar year, the Foundation team sets aside some days to plan for the following year. At that time, the team takes into account a number of determinants in coming up with the seminar program. These include the disease areas Garvan scientists research; feedback from past seminar attendees on their disease interests (that's why it's important to fill in your seminar evaluation form); and the quality of potential speakers. If there is demand for an area which is not one of Garvan's greatest strengths we will partner with other nonprofit organisations to meet this demand.

Our most popular seminars in recent years remain those which bring together both research and clinical information across several disease areas, such as Healthy Ageing and the Ageing Brain.

How does Garvan Research Foundation achieve its annual budget each year?

The Foundation is the Garvan's philanthropic fundraising arm, and as such, is set annual income targets by the Foundation Board and also held to a lean expenditure budget. In 2008, our income target is over \$7m.

The majority of this income currently derives from gifts by individuals who choose to support Garvan's breakthrough medical research, often people who have been directly or indirectly affected by one of the diseases we study and who value Garvan's work and reputation. Some supporters choose to dedicate their gift specifically to a program or project, whereas others are happy to have Garvan direct it to the greatest areas of need in research. Supporters either make gifts in response to our appeals; initiate the gift themselves; or if it is a major gift, will be asked by the CEO after a process of relationship-building. Bequests are also a significant income category for Garvan. Some income is also drawn from the corporate sector, often through corporate foundations.

The Foundation maintains a small team (six - seven staff), so our only significant expenditures are in salaries and the costs of appeals and other marketing materials. We do not use external fundraisers or consultants, which is something supporters ask about as they have read stories about charities which expend a great deal of money on this. We work hard to contribute more income and incur less expenditure than expected, and over the past three years, we have succeeded.




Personalised Cancer Care

The explosion of genetic information about subtypes of cancer is generating exciting possibilities for the development of personalised approaches to the diagnosis and treatment of cancer, and Garvan researchers are leading the way.


Personalised medicine combines knowledge of the underlying biology of a cancer and the unique aspects of a patient to determine the most appropriate treatment for that person.

Cancer is more than one disease

Personalised medicine goes above and beyond conventional medical practice. In most cases, the conventional approach is based on a reactive assessment of a patient's medical state, which is determined by a combination of clinical signs and measurements such as blood tests. Based on these assessments a doctor makes a diagnosis and prescribes the appropriate course of treatment. This approach doesn't take into account the unique genetic makeup of the individual's cancer. We now know that cancer develops as a result of multiple genetic and epigenetic changes to the genetic sequence and the way the sequence is interpreted. We also know that individuals with the same type of cancer often have different defects in their cancer.



Breast cells growing in culture. They are 'expressing', or producing, a green fluorescent protein, while their nucleus is stained with a blue dye.



A basal breast cancer stained with an antibody to Id1- every cell with a brown nucleus is expressing Id1

This explains why people with similar cancers respond differently to the same anticancer drugs.

This is where personalised medicine steps in. Using the knowledge of the underlying biology of the cancer and unique aspects of the patient we can target the most appropriate treatment to an individual patient, and minimise unnecessary adverse side effects. To this end, Garvan researchers in the Cancer Research Program are working to identify molecular markers that can be used to classify subtypes of particular cancers depending on their likely prognosis and response to therapy.

Breast Cancer

It is always the clinician's aim to achieve early diagnosis in order to implement appropriate therapies early to minimise the risk of relapse and improve the survival rate of the patient. Hormone therapy has proven to be a key factor in achieving these treatment outcomes. The therapy works by inhibiting cancer cells from getting

or using the natural hormones they need to grow such as oestrogen. A simple lab test can determine the presence of hormone receptors. If a test shows the presence of oestrogen receptors an ER positive cancer is diagnosed. A cancer presenting without these receptors is classified as ER negative. This distinction has important implications for treatment. ER positive cancers require a drug that targets and blocks oestrogen action in breast cancer leading in many cases to improved patient survival and a reduction in disease recurrence. The most successful of these drugs is Tamoxifen.

However, 25% of women with ER positive breast cancers do not respond to treatment with Tamoxifen, and of those that respond initially a significant percentage can develop resistance to treatment over time, leading to a recurrence of the disease.

Another highly successful breast cancer treatment, Herceptin (which acts on the protein HER2 found in 15-20% of breast tumours) has also shown excellent results in


controlling disease. However, only 30% of women who test positive for HER2 respond to Herceptin.

These statistics clearly show there are still profound gaps in knowledge about the genetic basis of many breast cancers (and cancers in general), which means personalised medicine offers huge potential for sufferers of this devastating disease. Garvan cancer researchers are working hard to bridge this gap by understanding the underlying molecular biology of cancer subtypes and why they are resistant to therapy and by identifying new molecular markers of disease.

A research team lead by Associate Professor Liz Musgrove and Professor Rob Sutherland is working to identify genes that impact the sensitivity of breast cancer cells to drugs like Tamoxifen. These genes may represent potential new markers of therapeutic resistance and provide new drug targets for patients resistant to treatment with Tamoxifen and the newer aromatase inhibitors.

The research of the Signal Transduction Group, headed by Professor Roger Daly, is focused on proteins involved in the transmission of signals in breast cancer cells. Basal breast cancers lack ER and HER2 so that they are resistant to drugs like Tamoxifen and Herceptin and have a poor outcome. Professor Daly's group is currently involved in research aimed at identifying the signaling pathways involved in basal-type breast cancer in order to identify new drug targets for this group of cancers.

Dr Alex Swarbrick's research group is also investigating the genetics of basal breast cancer and has recently shown that the Id1 gene is very active in these cancers. However, by 'switching off' this gene it is possible to induce a state of 'senescence', or permanent sleep, within a tumour, preventing it from growing and metastasizing (spreading to other organs in the body). These results suggest that in the future by therapeutically targeting the Id1 gene we may be able to force basal breast cancer to senesce, giving new hope to women with this aggressive and metastatic form of breast cancer.



The lymph node of a mouse carrying a breast cancer that expresses a green fluorescent protein. The green patches are cancer cells that have metastasised to the lymph node.

Prostate Cancer

Unlike breast cancer, there are no widely accepted molecularly targeted therapies for prostate cancer, which limits treatment options to surgery or radiotherapy. Early detection is one of the most important factors in controlling the disease and this can involve

a digital rectal examination or a prostate-specific antigen (PSA) test that measures the level of PSA in the blood. PSA is made by the prostate and can be found in an increased amount in the blood of men who have prostate cancer. However, the PSA test is not able to predict accurately which patients will develop aggressive life-threatening prostate cancer, and therefore require more aggressive treatment.

Encouragingly, researchers in Garvan's Prostate Cancer Group led by Associate Professor Sue Henshall have found that men with low levels of a marker called AZGP1 in the prostate at the time of surgery have a greatly increased risk of the disease spreading to other parts of the body (known as metastatic cancer). This means that these men could benefit from more aggressive treatment such as radiotherapy or chemotherapy at the time of surgery when the cancer is potentially curable. Alternatively, patients with low levels of AZGP1 are at low risk of developing metastatic cancer and therefore could defer a more aggressive treatment with major impacts on quality of life.

Apart from breast and prostate cancer, Garvan's internationally recognised Cancer Research Program also studies colorectal (bowel), lung, ovarian and pancreatic cancer – these are amongst the most commonly diagnosed and lethal cancers.



Staff Profile: Ebi Cocodia



What do you enjoy about working at Garvan?

I enjoy the 'small community' feel of Garvan. Having recently joined Garvan as the Co-ordinator, Graduate Student Program I also enjoy the everyday challenge of a developing role. I like that everyone's helpful here.

Describe a typical day.

The Garvan Institute recruits postgraduate students twice a year. As most of our students are enrolled through the University of New South Wales my typical day involves candidature management and administration of the postgraduate student program here. This is very broad and includes liaising with the university, problem-solving, updating policy, providing policy advice to students, supervisors and the Higher Degree Committee. For instance a typical day may involve student training, pastoral care or following up on individual students' progress which may entail developing strategies to ensure students complete their studies within the stipulated time frame. In addition, I'm constantly sourcing high-quality prospective students to join us at the Garvan Institute.

What challenges are there working at Garvan?

The challenge is to emphasise the importance of adhering to new and existing policies to faculty and students.

What do you enjoy doing away from Garvan?

I volunteer with community and church groups during my spare time. I also enjoy reading non-fiction immensely.

Volunteer Profile: Joan and Robert Neilson

Joan and Robert Neilson, married in 1963, have been volunteers at Garvan Research Foundation, cumulatively for over 13 years. Joan commenced in 1999, and also spent over 3 years as a volunteer guide for patients enrolled in clinical trials associated with the Bone Program. Robert has spent about 5 years providing assistance at our public seminars.

Joan started her 35 year nursing career training at Prince Henry Hospital, Little Bay followed by a year's training in Obstetrics at Royal Hospital for Women, Paddington. To gain further experience she worked at Royal Prince Alfred Hospital, Camperdown and Concord Hospital.

Robert was employed in the Sydney City Council and in 1993 attained the position of Principal Draftsman, Survey Drafting Section which included Land Information Systems. As the City Council was responsible for the formation of the State Emergency Service unit for Sydney Robert joined the SES in 1966. He became Local Controller until he stood down in 2000 to become Liaison Officer. On a rotation basis he still carries out the responsibility of the Duty Officer's Role.

The State Emergency Service is the combat agency for storms and floods. During a severe storm which lashed Sydney some years ago the unit received a call from the Garvan for assistance. It appeared that the building had lost power and as such was in danger of losing valuable blood samples. The SES were able to organise the delivery of generators. With the passage of time and technical improvements the Garvan has now its own generators and Internet freezers.



Robert and Joan Neilson with Carole Renouf (middle), CEO of the Garvan Research Foundation.



From the collection an 18ct white gold diamond dress ring.

A Precious Gift

Garvan is extremely grateful to Drs James and Babette Ryan who, in their passing, have bequeathed a very precious gift. As strong supporters of Garvan's research, the Ryans generously donated the balance of their estate including fine jewellery (gold, diamond and precious stone rings, brooches, pendants and necklaces, Cartier and Rolex gold and diamond set ladies' watches), a collection

of Royal Australian Mint \$200 Gold Proof coins and a rare Chinese ivory and bamboo Mah Jong boxed set.

With the support of GraysOnline, Garvan will be auctioning these very special items online at www.graysonline.com.au from 31st July to 6th August. The auction will be unreserved, with bidding on all items starting at only \$9.

Dr James Ryan was recognised for his outstanding service in the development, teaching and practice of radiology in Australia and New Zealand and was one of only 23 recipients of the Gold Medal established by the Royal Australian and New Zealand College of Radiologists. The Ryans would be comforted to know their precious gift is contributing to advancing medical research. To get a closer look you can view the collection at Garvan. Details of the viewing can be found at www.graysonline.com.au

GARVAN OPEN DAY

SUNDAY 17 AUGUST 2008 10AM – 1PM



Our research. Your Health. A Day of Discovery.

If you happen to see a bigger buzz than usual around Darlinghurst on **Sunday 17th August**, don't be alarmed. The reason is Garvan is holding its first ever Open Day for the public, and we expect the wealth of information and interactive activities on offer will attract considerable attention. We hope you can join us, along with your family and friends.

Open Day will feature two very special guest presenters: Mikey Robins (Good News Week, Vega FM breakfast host) and Robyn Williams (ABC Radio National's Science Show host). They will join some of the sharpest minds in Australia to address the all important issue "The Future of Science and Medicine". The panel will include Garvan Executive Director Professor John Shine, and leading Endocrinologist and Head of Garvan's Bone Research Program, Professor John Eisman.

Our world-renowned scientists are excited to share their science. You will have the chance to meet them face-to-face and hear how they are tackling major diseases such as cancer, diabetes, hearing loss, osteoporosis, autoimmune disorders and eating disorders.

If you have a particular interest in cancer or diabetes come to our special presentations on the latest breakthrough research by Garvan and the implications for your health.

There will be tours of Garvan running throughout the day and a disease expo where you can talk directly with our scientists about their work. Refreshments (including great coffee by Vittoria) will be available for purchase from our rooftop café. **Open Day is FREE and runs from 10am – 1pm.** The activity schedule is:

Tours: 10:20am, 10:50am, 11:20am, 11:50am

Research Updates: Cancer 10:30am, Type 2 Diabetes 11am

Panel Discussion: The Future of Science and Medicine 11:40am-12:40pm

Disease Information Expo: Anytime 10am – 1pm

For more information call (02) 9295 8110 or visit www.garvan.org.au.

Donor Update

In the first half of 2008, 4,010 people and organisations have supported Garvan's work. This includes 1,925 who have given to us for the first time this year. We thank you all for your generosity and for your belief in our research.

Keeping up to date with Garvan's progress

This newsletter and our appeal letters are ways we keep our supporters up to date with the progress we are making together towards understanding the causes and processes of disease.

However, to get up to the minute news you can visit our web-site homepage at www.garvan.org.au. You can also read full versions of our current and past press releases in our **News** section; and see which events are coming up by clicking on **Events**. In both sections you can subscribe to an RSS feed by clicking on the RSS icon, as seen below.



New On-Line Supporter Centre

We have also recently launched the Supporter Centre section of our web-site under the Support Us page. You can use the forms on this section to change your communication options, update your credit card details, change your address or simply ask us a question or send in a comment.

As always we look forward to hearing from you in whichever way is most convenient. You can contact us by phone on **1300 73 66 77** (9am to 5pm EST), email foundation@garvan.org.au, or on the web www.garvan.org.au.

Volunteers Needed for Clinical Trials

Garvan regularly recruits members of the community to participate in our clinical trials. If you meet the various prerequisites and are interested in helping with our research in this way, then we would like to hear from you.

BODY WEIGHT AND ENERGY STUDY: Are you aged between 40 and 80 years old? Are you taking a medication for blood pressure, migraines or tremor? If you answered "yes" to these questions, we invite you to participate in a study investigating the relationship between energy and body and weight.

Are you aged between 40 and 80 years old? Are you healthy? We would like to hear from you to participate in the same study.

For more information, please contact **Dr Paul Lee** on (02) 9295 8486 or email p.lee@garvan.org.au

DIABETES TREATMENT STUDY: We require volunteers with Type 2 diabetes aged 40-80yrs who are treated with diet and/or Diabex, Diaformin or Glucophage, but not treated with other diabetes tablets or insulin.

For further information please contact **Olivia Wong** or **Ashley Douglas** on (02) 9295 8233 or email o.wong@garvan.org.au

RESEARCH INTO BODY FAT AND HORMONES: Are you a healthy male between the age of 50-80 years? We are investigating the effects of two commonly used medications, Raloxifene and Tamoxifen, on the burning of fat and protein in the body. Involves visits over a 10 week time period. Please ring **Dr Vita Birzniece** (02) 9295 8486 or **Amanda Xuereb** (02) 9295 8232 for further information.

Coming Up

Don't forget to mark these dates in your diary:

Thursday 7th August
Osteoporosis Free Public Seminar
 10am-12:30am (doors open at 9am)
 Registration required

Sunday 17th August
Garvan Open Day
 10am – 1pm
 Registration not necessary

Wednesday 3rd September
Asthma and Allergies Free Public Seminar
 6pm – 8pm (doors open 5:30pm)
 Registration required

All events are held at the Garvan Institute 384 Victoria Street Darlinghurst. To register for seminars please call (02) 9295 8110 or register online at www.garvan.org.au

The 2008 Free Public Seminar Series is generously sponsored by the Alcoa Foundation.

In memoriam February 08 - June 08

We gratefully acknowledge gifts received in memory of:

Gordon Adamson
 Tessa Birnie
 Peter Boersma
 Victor John Bryers
 Anna Costan
 Nick Damoulakis
 Michael John Ditchburn

Denis Farrow
 Lorraine Gee
 Deborah George
 Keith Gould
 Joan Harrison
 Geoffrey Ronald Hewitt
 Steven Ivezic

Frank Michael Jones
 Valerie May Jorgensen
 Lillian May (Billie) Nelson
 Cosimo Nocera
 Angus Norman
 Margaret Scott
 Mary Seymour
 Jane Wilson
 Graham Wright
 Millicent Wright

Be part of progress

Please use this coupon if you would like to make a donation to Garvan's breakthrough medical research, or if you would like further information. We would love to hear from you.

My Contact Details

Title _____ First name _____

Surname _____

Address _____

Suburb _____ State _____ Postcode _____

Daytime Phone _____

Email _____

Garvan Supporter Number (if known) _____

Please Send Me Further Information About:

- Giving to Garvan in my will (strictly confidential)
- Volunteering with Garvan
- Giving regularly to Garvan through my bank account

Please Change My Contact Details:

- I no longer wish to receive *breakthrough*
- I only wish to receive *breakthrough* by email
- I only wish to receive appeal mailings in May/June
- I do not wish to receive any appeal mailings

My Gift Details

Yes! I want to help Garvan make progress with a gift of:

Gift of choice \$ _____ \$50 \$100 \$250 \$500 \$1000

My cheque/money order made payable to **Garvan Research Foundation** is enclosed

OR Please deduct the above amount once monthly annually from my Visa Mastercard Diners Amex

Card Number

Expiry Date 2008BT02

Cardholder's Name _____

Signature _____

Please complete this coupon and mail it to:

Garvan Research Foundation,
 Reply Paid 68593, Darlinghurst NSW 2010

Call: 1300 73 66 77 (9am to 5pm)

Fax: (02) 9295 8151
 (you can use this coupon)

Online: www.garvan.org.au



**GARVAN
 INSTITUTE**